title: Strategies to prevent BK virus infection in kidney transplant recipients.
abstract: Despite improvements in posttransplant care, BK virus (BKV) remains one of the most challenging posttransplant infections in kidney transplant recipients with high rates of allograft failure. In the absence of well tolerated and efficacious viral specific therapeutics, treatment is primarily focused on reduction of immunosuppression, which poses a risk of rejection and fails to lead to viral clearance in a number of patients.
  
  
  
  Recent work has turned toward preventive therapies analogous to those used for other infections like cytomegalovirus. These efforts have focused on the use of quinolone antibiotic prophylaxis to prevent BKV infection and pretransplant vaccination to boost humoral and cellular immunity.
  
  
  
  Despite promising in-vitro and observational data, quinolone antibiotic prophylaxis has not been effective in preventing BKV infection in prospective studies. However, prophylaxis with newer less toxic viral specific agents such as brincidofovir - the lipid oral formulation of cidofovir - may yet prove effective. Strategies focused on eliciting a humoral immune response to recombinant virus-like particles or using adoptive transfer of BKV-specific T cells have also shown significant potential to prevent BKV infection in organ transplant recipients.
authors.affiliation: aDivision of Infectious Disease bDivision of Nephrology, University of British Columbia cCentre for Health Evaluation and Outcome Sciences, Vancouver, British Columbia, Canada.
authors.forename: Alissa J
authors.initials: AJ
authors.lastname: Wright
authors.forename: John S
authors.initials: JS
authors.lastname: Gill
mesh_terms: D001739:BK Virus; D003596:Cytosine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007111:Immunity, Cellular; D056724:Immunity, Humoral; D007165:Immunosuppression Therapy / Q000009:adverse effects; D016030:Kidney Transplantation; D063065:Organophosphonates / Q000627:therapeutic use; D027601:Polyomavirus Infections / Q000517:prevention & control*; D011183:Postoperative Complications / Q000517:prevention & control* / Q000821:virology; D011446:Prospective Studies; D015363:Quinolones / Q000627:therapeutic use; D066027:Transplant Recipients; D014412:Tumor Virus Infections / Q000517:prevention & control*
chemical_list: D063065:Organophosphonates; D015363:Quinolones; C525733:brincidofovir; D003596:Cytosine